Therapeutic activity of an anti-idiotypic antibody-derived killer peptide against influenza a virus experimental infection

Antimicrobial Agents and Chemotherapy

Volumn 52, Issue 12, 2008, Pages 4331-4337

  Conti, Giorgio ^a   Magliani, Walter ^a   Conti, Stefania ^a   Nencioni, Lucia ^b   Sgarbanti, Rossella ^b   Palamara, Anna Teresa ^b   Polonelli, Luciano ^a  

^a UNIVERSITY OF PARMA   (Italy)

^b SAPIENZA UNIVERSITY OF ROME   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

HEMAGGLUTININ; HUMAN IMMUNODEFICIENCY VIRUS ANTIBODY; IDIOTYPIC ANTIBODY; KILLER DECAPEPTIDE; MEMBRANE PROTEIN; PEPTIDE DERIVATIVE; TOXIN; UNCLASSIFIED DRUG; VIRUS PROTEIN;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIMICROBIAL ACTIVITY; ARTICLE; CELL LINE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG INHIBITION; DRUG MECHANISM; EXPERIMENTAL INFECTION; HEMADSORPTION; HEMAGGLUTINATION; IN VITRO STUDY; IN VIVO STUDY; INFLUENZA; INFLUENZA VIRUS A; INFLUENZA VIRUS A H1N1; LUNG; MALE; MOUSE; NONHUMAN; PRIORITY JOURNAL; SURVIVAL; VIRUS CULTURE; VIRUS PARTICLE; VIRUS REPLICATION; VIRUS STRAIN; YEAST;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIVIRAL AGENTS; CELL LINE; HUMANS; INFLUENZA A VIRUS, H1N1 SUBTYPE; KILLER FACTORS, YEAST; LUNG; MALE; MICE; MICE, INBRED BALB C; ORTHOMYXOVIRIDAE INFECTIONS; PEPTIDES; TREATMENT OUTCOME; VIRAL PROTEINS; VIRUS REPLICATION;

EID: 57049111193     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00506-08     Document Type: Article

References (38)

1. Alexander, M. E., C. S. Bowman, Z. Feng, M. Gardam, S. M. Moghades, G. Rost, J. Wu, and P. Yan. 2007. Emergence of drug resistance: implications for antiviral control of pandemic influenza. Proc. Biol. Sci. 274:1675-1684.
2. Barbey-Martin, C., B. Gigant, T. Bizebard, L. J. Calder, S. A. Wharton, J. J. Skehel, and M. Knossow. 2002. An antibody that prevents the haemagglutinin low pH fusogenic transition. Virology 294:70-74.
3. Borland, R., and B. W. Mahy. 1968. Deoxyribonucleic acid-dependent ribonucleic acid polymerase activity in cells infected with influenza virus. J. Virol. 2:33-39.
4. Casoli, C., E. Pilotti, C. F. Perno, E. Balestra, E. Polverini, A. Cassone, S. Conti, W. Magliani, and L. Polonelli. 2006. A killer mimotope with therapeutic activity against AIDS-related opportunistic micro-organisms inhibits ex-vivo HIV-1 replication. AIDS 20:975-980.
5. Cenci, E., F. Bistoni, A. Mencacci, S. Perito, W. Magliani, S. Conti, L. Polonelli, and A. Vecchiarelli. 2004. A synthetic peptide as a novel anticryptococcal agent. Cell. Microbiol. 6:953-961.
6. Cenci, E., E. Pericolini, A. Mencacci, S. Conti, W. Magliani, F. Bistoni, L. Polonelli, and A. Vecchiarelli. 2006. Modulation of phenotype and function of dendritic cells by a therapeutic synthetic killer peptide. J. Leukoc. Biol. 79:40-45.
7. De Clercq, E. 2006. Antiviral agents active against influenza A viruses. Nat. Rev. Drug Discov. 5:1015-1025.
8. Di Trani, L., A. Savarino, L. Campitelli, S. Norelli, S. Puzelli, D. D'Ostilio, E. Vignolo, I. Donatelli, and A. Cassone. 2007. Different pH requirements are associated with divergent inhibitory effects of chloroquine on human and avian influenza A viruses. Virol. J. 4:39.
9. Ferguson, N. M., D. A. Cummings, S. Cauchemez, C. Fraser, S. Riley, A. Meeyai, S. Iamsirithaworn, and D. S. Burke. 2005. Strategies for containing an emerging influenza pandemic in Southeast Asia. Nature 437:209-214.
10. Finter, N. B. 1964. Quantitative haemadsorption, a new assay technique. I. Assay of interferon. Virology 24:589-597.
11. Fiori, P. L., A. Mattana, D. Dessì, S. Conti, W. Magliani, and L. Polonelli. 2006. In vitro acanthamoebicidal activity of a killer monoclonal antibody and a synthetic peptide. J. Antimicrob. Chemother. 57:891-898.
12. Hierolzer, J. C., and R. A. Killington. 1996. Virus isolation and quantitation, p. 35-37. In B. W. J. Mahy and H. O. Kangro (ed.), Virology methods manual. Academic Press, London, United Kingdom.
13. Hurt, A. C., H. T. Ho, and I. Barr. 2006. Resistance to anti-influenza drugs: adamantanes and neuraminidase inhibitors. Expert Rev. Anti-Infect. Ther. 4:795-805.
14. Inglis, S. C., A. R. Carroll, R. A. Lamb, and B. W. Mahy. 1976. Polypeptides specified by the influenza virus genome. I. Evidence for eight distinct gene products specified by fowl plague virus. Virology 74:489-503.
15. Inglis, S. C., D. J. McGeoch, and B. W. Mahy. 1977. Polypeptides specified by the influenza virus genoma. 2. Assignement of protein coding functions to individual genome segments by in vitro translation. Virology 78:522-536.
16. Jefferson, T., V. Demicheli, D. Rivetti, M. Jones, C. Di Pietrantonj, and A. Rivetti. 2006. Antivirals for influenza in healthy adults: systematic review. Lancet 367:303-313.
17. Krueger, J. G., E. Wang, E. A. Garber, and A. R. Goldberg. 1980. Differences in intracellular location of pp60src in rat and chicken cells transformed by Rous sarcoma virus. Proc. Natl. Acad. Sci. USA 77:4142-4146.
18. Lamb, R. A., and P. W. Choppin. 1977. Synthesis of influenza virus polypeptides in cells resistant to alpha-amanitin: evidence for the involvement of cellular RNA polymerase II in virus replication. J. Virol. 23:816-819.
19. Le, Q. M., M. Kiso, K. Someya, Y. T. Sakai, T. H. Nguyen, K. H. Nguyen, N. D. Pham, H. H. Ngyen, S. Yamada, Y. Muramoto, T. Horimoto, A. Takada, H. Goto, T. Suzuki, Y. Suzuki, and Y. Kawaoka. 2005. Avian flu: isolation of drug-resistant H5N1 virus. Nature 437:1108.
20. Lipsitch, M., T. Cohen, M. Murray, and B. R. Levin. 2007. Antiviral resistance and the control of pandemic influenza. PLoS Med. 4:e15.
21. Longini, I. M., Jr., A. Nizam, S. Xu, K. Ungchusak, W. Hanshaoworakul, D. A. Cummings, and M. E. Halloran. 2005. Containing pandemic influenza at the source. Science 309:1083-1087.
22. Magliani, W., S. Conti, A. Salati, S. Vaccari, L. Ravanetti, D. L. Maffei, and L. Polonelli. 2004a. Therapeutic potential of yeast killer toxin-like antibodies and mimotopes. FEMS Yeast Res. 5:11-18.
23. Magliani, W., S. Conti, A. Salati, S. Arseni, L. Ravanetti, R. Frazzi, and L. Polonelli. 2004b. Engineered killer mimotopes: new synthetic peptides for antimicrobial therapy. Curr. Med. Chem. 11:1793-1800.
24. Matthews, T., M. Salgo, M. Greenberg, J. Chung, R. DeMasi, and D. Bolognesi. 2004. Enfuvirtide: the first therapy to inhibit the entry of HIV-1 into host CD4 lymphocytes. Nat. Rev. Drug Discov. 3:215-225.
25. Mori, I., B. Liu, M. J. Hossain, H. Takakuwa, T. Daikoku, Y. Nishiyama, H. Naiki, K. Matsumoto, T. Yokochi, and Y. Kimura. 2002. Successful protection by amantadine hydrocloride against lethal encephalitis caused by a highly neurovirulent recombinant influeza A virus in mice. Virology 303: 287-296.
26. Nayak, D. P., E. K. Hui, and S. Barman. 2004. Assembly and budding of influenza virus. Virus Res. 106:147-165.
27. Ong, A. K., and F. G. Hayden. 2007. John F. Enders lecture 2006: antivirals for influenza. J. Infect. Dis. 196:181-190.
28. Palamara, A. T., L. Nencioni, K. Aquilano, G. De Chiara, L. Hernandez, F. Cozzolino, M. R. Ciriolo, and E. Garaci. 2005. Inhibition of influenza A virus replication by resveratrol. J. Infect. Dis. 191:1719-1729.
29. Polonelli, L., W. Magliani, S. Conti, L. Bracci, L. Lozzi, P. Neri, D. Adriani, F. De Bernardis, and A. Cassone. 2003. Therapeutic activity of an engineered synthetic killer anti-idiotypic antibody fragment against experimental mucosal and systemic candidiasis. Infect. Immun. 71:6205-6212.
30. Santoro, M. G., C. Favalli, A. Mastino, B. M. Jaffe, M. Esteban, and E. Garaci. 1988. Antiviral activity of a synthetic analog of prostaglandin A in mice infected with influenza A virus. Arch. Virol. 99:89-100.
31. Santoro, M. G., C. Amici, G. Elia, A. Benedetto, and E. Garaci. 1989. Inhibition of virus protein glycosylation as the mechanism of the antiviral action of prostaglandin A in Sendai virus-infected cells. J. Gen. Virol. 70: 789-800.
32. Savoia, D., S. Scutera, S. Raimondo, S. Conti, W. Magliani, and L. Polonelli. 2006. Activity of an engineered synthetic killer peptide on Leishmania major and Leishmania infantum promastigotes. Exp. Parasitol. 113:186-192.
33. Shigeta, S., S. Mori, J. Watanabe, S. Soeda, K. Takahashi, and T. Yamase. 1997. Synergistic anti-influenza virus A (H1N1) activities of PM-523 (polyoxometalate) and ribavirin in vitro and in vivo. Antimicrob. Agents Chemother. 41:1423-1427.
34. Sidwell, R. W., and D. F. Smee. 2000. In vitro and in vivo assay systems for study of influenza virus inhibitors. Antivir. Res. 48:1-16.
35. Sveda, M. M., L. J. Markoff, and C. J. Lai. 1984. Influenza virus hemagglutinin containing an altered hydrophobic carboxy terminus accumulates intracellularly. J. Virol. 49:223-228.
36. Travassos, L. R., L. S. Silva, E. G. Rodrigues, S. Conti, A. Salati, W. Magliani, and L. Polonelli. 2004. Therapeutic activity of a killer peptide against experimental paracoccidioidomycosis. J. Antimicrob. Chemother. 54: 956-958.
37. Watabe, T., H. Kishino, L. de Oliveira Martins, and Y. Kitazoe. 2007. A likelihood-based index of protein binding affinities with application to influenza HA escape from antibodies. Mol. Biol. Evol. 24:1627-1638.
38. World Health Organization. 2005. WHO global influenza preparedness plan. The role of WHO and recommendations for national measures before and during pandemics. World Health Organization, Geneva, Switzerland. http://www.who.int/csr/resources/publications/influenza/ WHO_CDS_CSR_GIP_2005_5Eweb[1].pdf. Accessed 10 September 2007.